guselkumab

Home
Ligands
guselkumab

GtoPdb Ligand ID: 7998

Synonyms: CNTO-1959 | Tremfya®

guselkumab is an approved drug (EMA & FDA (2017))

Comment: Guselkumab is a monoclonal antibody directed against interleukin-23A (IL23A). It is being investigated as a treatment for plaque psoriasis.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.

Immunopharmacology Comments
Anti-IL-23 mAbs act upstream of the IL-17/T_H17 pathway [3] in autoimmune inflammation. Utilising IL-23-selective biologic therapeutics (that do not act on the T_H1 cell immune response) are expected to offer an improved safety profile compared to IL-17-targeting therapeutics. Other anti-IL-23 clinical candidates include tildrakizumab (Sun Pharmaceutical Industries) and risankizumab (AbbVie).

Immunopharmacology Comments

Anti-IL-23 mAbs act upstream of the IL-17/T_H17 pathway [3] in autoimmune inflammation. Utilising IL-23-selective biologic therapeutics (that do not act on the T_H1 cell immune response) are expected to offer an improved safety profile compared to IL-17-targeting therapeutics. Other anti-IL-23 clinical candidates include tildrakizumab (Sun Pharmaceutical Industries) and risankizumab (AbbVie).

Immunopharmacology Disease
Disease	X-Refs	Comment	References
Psoriasis	Disease Ontology: DOID:8893	First anti-IL-23 biologic therapy to be approved. Approved for the treatment of moderate to severe plaque psoriasis, in patients considered as candidates for systemic therapy or phototherapy.